The Future of Medicine is Data

OwkinAt the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new drugs to patient treatment decisions.

At 3pm (PST) on Tuesday the 10th of January at the Golden Gate Hotel, San Francisco, Thomas will discuss how finding the right treatment for every patient can only be achieved by the secure analysis of high-quality data, with data flowing freely yet securely between care and research. He will argue that allowing access to multimodal, KOL-selected and longitudinal patient data at scale and breaking research and competitive silos - while safeguarding security and privacy - are crucial to achieving precision medicine.

He will also highlight two technologies that Owkin is pioneering: firstly, using federated learning in clinical settings to create robust and global AI datasets, and secondly, using AI to gain a multiscale understanding of cause and effect in cancer biology, allowing researchers to predict how molecular perturbations impact cells, the tumor microenvironment and a patient’s outcome.

Thomas will outline how Owkin is delivering this vision by sharing Owkin’s recent successes in enhancing both biopharmaceutical research and care through unprecedented academic and industry collaborations, landmark strategic drug discovery and development partnerships, and the launch of world-first AI diagnostic solutions.

At last year's conference, Thomas outlined the limits of the historic applications of AI in drug discovery, arguing instead that AI should be used as an interactive tool that biologists, developers and physicians can use to co-create new knowledge.

Attending the conference alongside Thomas will be Alban de La Sablière, Chief Business Officer, Anna Huyghues-Despointes, Chief Corporate Development Officer, Jean-Frédéric Petit-Nivard, Chief Commercial Officer, and Joseph Lehár, SVP R&D Strategy.

Learn more about the 41st Annual J.P. Morgan Healthcare Conference, held in San Francisco from the 9th to the 12th of January.

About Thomas Clozel MD

Thomas Clozel MD is Co-founder and CEO of Owkin, leading medical research and business intelligence. He is a former Assistant Professor of Clinical Onco-Hematology at Hopital Henri Mondor in Paris and a former member of Ari Melnick's lab at the Weill Cornell Medical College, where he co-led several projects focused on prediction of resistance to chemotherapy in B-cell lymphoma. He co-founded Owkin with Gilles Wainrib in 2016.

About Owkin

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner.

We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data.

Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

Most Popular Now

Open Medical Works with Moray's Dig…

Open Medical is working with the Digital Health & Care Innovation Centre’s Rural Centre of Excellence on a referral management plan, as part of a research and development scheme to...

Generative AI on Track to Shape the Futu…

Using advanced artificial intelligence (AI), researchers have developed a novel method to make drug development faster and more efficient. In a new paper, Xia Ning, lead author of the study and...

AI could Help Improve Early Detection of…

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center suggests that artificial intelligence (AI) could help detect interval breast cancers - those that develop between...

Reorganisation, Consolidation, and Cuts:…

NHS England has been downsized and abolished. Integrated care boards have been told to change function, consolidate, and deliver savings. Trusts are planning big cuts. The Highland Marketing advisory board...

AI-Human Task-Sharing could Cut Mammogra…

The most effective way to harness the power of artificial intelligence (AI) when screening for breast cancer may be through collaboration with human radiologists - not by wholesale replacing them...

AI Tool Uses Face Photos to Estimate Bio…

Eyes may be the window to the soul, but a person's biological age could be reflected in their facial characteristics. Investigators from Mass General Brigham developed a deep learning algorithm...

Siemens Healthineers infection Control S…

Klinikum Region Hannover (KRH) has commissioned Siemens Healthineers to install infection control system (ICS) at the Klinikum Siloah hospital. The ICS aims to effectively tackle nosocomial infections and increase patient...

Philips Future Health Index 2025 Report …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled its 2025 Future Health Index U.S. report, "Building trust in healthcare AI," spotlighting the state of...

AI-Powered Precision: Unlocking the Futu…

A team of researchers from the Department of Diagnostic and Therapeutic Ultrasonography at the Tianjin Medical University Cancer Institute & Hospital, have published a review in Cancer Biology & Medicine...

AI Model Improves Delirium Prediction, L…

An artificial intelligence (AI) model improved outcomes in hospitalized patients by quadrupling the rate of detection and treatment of delirium. The model identifies patients at high risk for delirium and...

Building Trust in Artificial Intelligenc…

A new review, published in the peer-reviewed journal AI in Precision Oncology, explores the multifaceted reasons behind the skepticism surrounding artificial intelligence (AI) technologies in healthcare and advocates for approaches...

SALSA: A New AI Tool for the Automated a…

Investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Radiomics Group, led by Raquel Perez-Lopez, have developed SALSA (System for Automatic Liver tumor Segmentation And detection), a fully automated deep...